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There is a need to improve the ability of subunit vaccines to induce CD81 CTL responses in humans, especially for
vaccines used to prevent illness by organisms that undergo antigenic variation at their major neutralizing antibody sites, e.g.,
influenza A viruses and human immunodeficiency virus. Murine models have demonstrated the protective role of cross-
reactive CTL against influenza A virus antigenic drift. We tested the ability of an adjuvanted carrier (Iscomatrix) to help human
antigen-presenting cells present formalin-killed influenza vaccine to human CD81 CTL clones in vitro and in vaccinated
humans. The results of a randomized, double-blind, controlled clinical study demonstrate that a single dose of a vaccine
formulated into Iscom particles increased influenza A virus-specific CTL memory in 50–60% of recipients, compared to 5%
of the recipients of the standard influenza vaccine. © 1999 Academic Press
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hIntroduction. Influenza vaccines are composed of for-
alin-inactivated, detergent-disrupted virus, which is not
fficient for MHC class I processing, but is designed to
nduce neutralizing antibodies to the major antibody
ombining sites on the hydrophilic end of the hemagglu-
inin (HA-1) subunit. Due to frequent mutations at these
ites (1) the viral strains of influenza A (HI and H3) to be
sed in the vaccine need to be updated annually. Influ-
nza virus-induced T cell responses, however, have
uch greater strain cross-reactivity (2–5), and we are
nterested in whether augmenting cross-reactive T cell
emory might be an approach to improving influenza
accines. There are convincing data from murine models
hat such cross-reactive CD81 CTL responses can be
rotective (e.g., 6–10). We recognize that serotype-spe-
ific neutralizing antibody is the optimal approach to
revention of infection; nevertheless, in the presence of
ntigenic drift, cross-reactive memory CD81 CTL should
estrict virus replication, reduce lung disease, and pre-
ent deaths as they do in the mouse model. There is
ncreasing evidence that in certain circumstances pro-
eins and peptides can induce CD81 CTL responses in
ivo and these responses can correlate with protection
gainst challenge. Our laboratory reported that a fusion
rotein, which contained the influenza A (A/PR/8/34,
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (508) 856-4890. E-mail: Francis.Ennis@umassmed.edu.
2g
Current address: Intellivax International Inc., 5757 Cavendish Bou-
evard, Cote St. Luc, Quebec H4W 2WB, Canada.
042-6822/99 $30.00
opyright © 1999 by Academic Press
ll rights of reproduction in any form reserved.
2561N1) virus hemagglutinin HA2 subunit, induced CD81
TL in mice, and this correlated with a significant reduc-
ion in pulmonary virus titers and protection against le-
hal challenge (9, 10). The pulmonary virus reduction and
he survival from lethal challenge had the same speci-
icity as the CTL responses. In mice immunized with this
rotein, no neutralizing antibodies were induced and the
ung virus titers of all the H1 subtype virus strains tested
1934–1984) were significantly reduced despite antigenic
hanges at antibody combining sites (10). Lin and Asko-
as (6) had earlier reported the protective effect of a
D81 CTL NP-specific clone in mice challenged with
nfluenza A virus, and we noted cross-reactive reduction
n lung virus titers using a CD81 CTL clone specific for
n epitope on the NS1 protein (11). Other studies dem-
nstrated that osmotic shock (12) and the attachment of
fatty acid could help proteins and peptides induce
D81 T cell responses (13). Previous studies in humans
ith vaccines designed to induce or augment CTL re-
ponses to experimental vaccines, notably HIV-1 have
ielded negative or disappointing results, with only a
mall minority of individuals responding even to pox
irus-vectored genes (e.g., 14–16). We wanted to deter-
ine whether the formulation of standard influenza vac-
ine into an Iscom carrier, which has been reported to
ncrease murine antibody and CTL responses (17, 18),
ould augment CTL memory to influenza virus in hu-
ans. Iscoms are cage-like adjuvanted particles that
ave a diameter of approximately 30–40 nm, made up of
lycosides (Quill A), cholesterol, phospholipids, and the
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257RAPID COMMUNICATIONrotein or proteins of interest (17). A clinical study in
hich volunteers received under code (a) a standard
ose of trivalent influenza vaccine containing 15 mg each
f influenza A H1N1, H3N2, and influenza B virus sub-
nits, (b) the standard vaccine formulated into ISCOM
articles, or (c) a standard vaccine mixed with Iscomatrix
ut not formulated into particles. Clinical reactivity and
ntibody responses will be reported separately. The CTL
esults are reported in this article.
Results. Effects of Iscoms on specific recognition of
arget cells by human influenza A virus-specific CD81
TL clones. Table 1A contains the results of a CTL assay
ith a CD81 HA-specific CTL clone and autologous B-
CL target cells exposed to a monovalent formalin-inac-
ivated, detergent-disrupted A/Texas (H1N1) vaccine
lone or after mixing with Iscomatrix. As expected there
as no lysis of target cells exposed to the vaccine alone
1.4%), but there was a high level of specific lysis (76.6%)
f target cells pulsed with the vaccine–Iscom formula-
ion. Lysis of live virus-infected target cells was convinc-
ng as a positive control, and there was no lysis of target
ells exposed only to Iscomatrix without a vaccine com-
onent, as a negative control.
We next tested the ability of a CD81 CTL clone specific
or an HLA A2.1 restricted epitope on aa 122–130 of the
TABLE 1A
Recognition by HLA B18 Restricted HA-Specific Human CD81 CTL
Clone of A/Texas H1N1 Vaccine 6 Iscomatrix Pulsed BLCL
HA-Specific
clone
PR/8/34
Virus
A/Tx
Virus Iscomatrixa
A/TX
Vaccineb
A/TX
Flu-Iscomc
S 10-2F5d
(CD81) 53 33.8 21.6 1.4 76.6
in/Max 12.8 12.1 17.4 41.3 44.6
a Saponin concentration used was 337.5 mg/ml.
b HA concentration used was 82 mg/ml.
c HA concentration used was 57.5 mg/ml; saponin concentration was
37.5 mg/ml.
d E:T ratio 5 10:1 to measure percentage of specific lysis.
TA
Recognition by Human HLA A2.1 Restric
of Recombinant NS1 Prote
Clone Uninfected
NS1 Peptid
(aa 122–130
S 10-2C2e (CD81) 26.2 88.4
in/Max 17.8 19.6
a Peptide used at 25 mg/ml (killing observed down to 0.025 mg/ml a
b Protein used at 35 mg/ml.
c Saponin used at 100 mg/ml.
d Saponin used at 70 mg/ml.
e E:T ratio 5 10:1 to measure percentage of specific lysis.nfluenza A virus NS1 protein to recognize autologous
arget cells exposed to recombinant NS1 protein. This
lone is H1, H2, H3 subtype cross-reactive (19). The
esults in Table 1B demonstrate convincing killing of
arget cells pulsed with a peptide based on the se-
uence of aa 122–130 as the positive control and no lysis
f target cells not treated with peptide as a negative
ontrol. There was no lysis of target cells exposed to
ither the NS1 protein or the Iscomatrix alone, but there
as convincing lysis of target cells exposed to the mix-
ure of NS1 protein and Iscomatrix. The lack of lysis of
arget cells pulsed with the NS1 protein without Iscoms
as not due to a failure by the target cells to incorporate
he NS1 protein, because a CD41 CTL clone specific for
nother epitope on the NS1 protein lysed NS1 protein-
ulsed targets convincingly and to a similar degree when
dded alone or with Iscoms (data not presented).
Human CTL Responses to Vaccines. A clinical study
as performed in 55 healthy adults (ages 18–45 years)
nd CTL assays were performed on PBMC obtained from
amples of blood drawn on day 0 (prevaccination) and 14
nd 56 days after vaccination with a single immunization
ith a formalin-inactivated vaccine 6 Iscoms or Iscoma-
rix. We tested samples of PBMC obtained on days 0, 14,
nd 56 from each donor together in the same assay to
liminate variability of CTL assays performed on different
ays. In addition, we included as a positive control in
ach assay a well-characterized CTL clone to ensure
hat the virus-infected target cells were suitable for de-
ecting specific lysis in the CTL assay performed that
ay. All assays were performed and were interpreted
nder code.
The data shown in Table 2 are examples that reflect
he pattern of results observed in CTL assays performed
ith the PBMC of the 55 volunteers in the five vaccine
roups. Donor 013 shows a modest level of influenza A
irus-specific CTL memory on day 0 detected at multiple
ffector:target (E:T) ratios by the lysis of autologous tar-
ets infected with either the H1 or the H3 influenza A
iruses that were in the vaccine. The levels of lysis by the
B
1 aa 122–130-Specific CD81 CTL Clone
Iscomatrix Pulsed BLCL
NS1 Proteinb
NS1 Protein
1 Iscomb,c Iscomd
20.7 19.6 211.0
17.3 29.9 21.3BLE 1
ted NS
in and
e
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258 RAPID COMMUNICATIONirus-stimulated PBMC obtained 14 and 56 days after
accination were very similar to the prevaccination (day
) level; therefore, this individual did not have any
hange in influenza A virus-specific CTL memory after
accination. Most donors had these types of results.
onor 050 shows a different pattern. There is detectable
nfluenza A virus-specific CTL memory on day 0 but it is
ncreased significantly in the day 14 and 56 samples at
ultiple E:T ratios on both of the influenza A virus-
nfected target cells (P , 0.01). A third pattern of lysis is
emonstrated by Donor 031. No detectable level of spe-
ific CTL memory activity was observed with the day 0
BMC, but a modest and convincing level of CTL mem-
ry was detected on the postvaccination samples (P ,
.01) on days 14 and 56 at multiple E:T ratios and on
arget cells infected with the A/Texas (H1N1) or the
/Johannesburg (H3N2) viruses.
We interpreted the CTL data under code using a def-
nition that an increase in the postvaccination sample of
10% SIL above the day 0 level in at least 2/3 E:T ratios
as a 11 response, and an increase of $5% but less
han 10% in SIL over the day 0 level was a 1 response.
ncreases in levels of lysis of $5% were uniformly found
o be statistically significant. Increases in the percentage
ysis of ,5% were considered negative although some
alues were statistically significant. The CTL data were
ent to the clinical monitor who organized the results into
he vaccine groups. Table 3 summarizes the increases in
nfluenza A virus CTL memory in the three vaccine
roups. The CTL assay results showed a statistically
ignificant (P , 0.01) increases in influenza A-specific
TL memory on days 14 or 56 (5.0–37.5% increases) in
pproximately 50% of the assays performed on PBMC of
ndividuals who received one dose of vaccine formulated
TABLE 2
Bulk Culture Cytotoxic Activity by Effector Cells after Stimulation
ith the Homologous Virus of Infected Autologous Virus-Infected
arget Cellsa
E/T
Donor 013 Donor 050 Donor 031
A/TX A/JHN A/TX A/JHN A/TX A/JHN
ay 0 90 5.1% 11.3% 5.3% 17.2% 20.4% 21.1%
30 4.6% 8.6% 1.7% 10.0% 20.9% 1.1%
10 5.2% 6.7% 0.3% 6.6% 0.7% 0.8%
ay 14 90 1.2% 15.3% 22.1% 36.7% 4.1% 14.1%
30 3.1% 10.4% 15.1% 28.6% 2.0% 14.8%
10 5.6% 6.5% 8.6% 17.5% 2.0% 6.3%
ay 56 90 3.7% 12.7% 22.5% 35.8% 7.1% 19.9%
30 4.4% 12.7% 13.9% 25.2% 4.8% 12.0%
10 4.2% 6.2% 7.1% 20.4% 2.3% 7.4%
in/Max 14.6% 13.3% 17.7% 15.1% 16.2% 13.8%
a Values shown are (percentage lysis of virus-infected targets) 2 (%
ysis of uninfected targets). Lysis values of uninfected targets were all
6%.nto Iscoms and in about 30% of the assays of individualsiven vaccine mixed with the Iscomatrix, whereas only
% of the CTL assays of the recipients of the standard
accine had an increase in influenza A-specific CTL
emory.
Discussion. The results presented in this paper dem-
nstrate that it is possible to formulate protein antigens
o that they can be processed and presented by HLA
lass I molecules and be recognized by human CD81
TL clones in vitro. These results extend earlier reports
hat demonstrate murine CD81 cell recognition of
pitopes on proteins that entered cells treated with os-
otic shock or formulated into particles (13, 14). In these
xperiments we show that mixing with Iscomatrix en-
bled a formalin-killed monovalent influenza A virus vac-
ine to be recognized by a human hemagglutinin-spe-
ific CD81 CTL clone that is restricted by an HLA-B18. In
ddition, we found that an HLA 2.1 restricted epitope
ontained in a recombinant NS1 protein produced in
scherichia coli was also recognized on target cells by a
uman CD81 CTL clone after it was mixed with Iscoma-
rix; however, target B-LCL pulsed with the recombinant
rotein alone were not lysed.
These adjuvanted killed influenza vaccines also in-
reased influenza A virus CTL memory activity in humans
fter a single dose. The memory CTL increases were
een in more recipients of the Iscom-formulated vac-
ines, with a smaller number responding to the mixture
f vaccine and Iscomatrix. There was virtually no in-
rease in CTL memory responses seen in the recipients
f the standard vaccine alone. These increases in CTL
ctivity correlate with increases in the number of influ-
nza A virus CTL epitope peptide-specific IFNg-produc-
ng cells detected using the PBMC of some of these
TABLE 3
CTL Respondersa in the Flu-Iscom Phase 1 Trial
Virus
Flu-Iscom Flu-Iscomatrix
Fluzone
4550/45b 75/45 50/45 75/45
H1 (A/TX/36/91)
Nonresponders 4 6 10 7 11
5–10% 5 2 1 2 0
.10% 2 3 0 2 0
Responders 7 5 1 4 0
H3 (A/JHN/33/94)
Nonresponders 7 4 7 6 10
5–10% 2 5 2 3 0
.10% 2 2 2 2 1
Responders 4 7 4 5 1
a Subjects showing from 5 to 37.5% increases in specific immune
lysis in at least two E:T ratios by the day 14 or day 56 samples above
the level of lysis by the day 0 samples.
b numerator 5 dose of iscomatrix
denominator 5 dose of virus HA
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259RAPID COMMUNICATIONaccinees (Jameson et al., unpublished data). These re-
ults demonstrate that quality-controlled human CTL as-
ays can detect statistically significant increases in vi-
us-specific CTL memory following administration of one
ose of an inactivated vaccine. Furthermore, the findings
emonstrate that formulating the vaccine as an Iscom, or
ven mixing the vaccine with Iscomatrix, results in aug-
ented human CTL activity in vaccine recipients, which
as consistent with the results of our preclinical in vitro
uman CTL assays. The results suggest that in vitro
nalysis with human T cell clones may be useful in
redicting human immunogenicity and thus help to re-
uce the number of experimental constructs used in
nimal immunogenicity assays for the preclinical as-
essment of candidate vaccines.
It will be important to extend these types of studies of
uman CTL responses to other vaccines. The CD81 CTL
esponses to experimental HIV-1 vaccines have been
ery disappointing (14–16). A minority of vaccinees ap-
ear to develop CTL response even to pox-virus vectored
accines, despite the use of multiple doses. The CTL
ata in the literature in response to HIV-1 vaccines are
ifficult to interpret. The PBMC of recipients of HIV-1
xperimental vaccines were usually tested only after
ultiple doses often with dissimilar antigens, e.g., pox-
ector priming and boosting with recombinant antigens,
nd fresh PBMC were tested in CTL assays; therefore
re- and postvaccine dosage samples of PBMC were not
irectly compared. Although cryopreservation is known
o reduce the cytotoxic activity of activated T and NK
ells, the PBMC of vaccine donors before and several
eeks to months after receipt of an inactivated or sub-
nit vaccine are not likely to contain activated cytotoxic T
ells, but may contain vaccine-induced memory CTL.
nother practical concern about the application of such
uality-controlled CTL assays may be the work involved.
uman CTL assays are complex, but the simultaneous
esting of all samples from each donor in the same CTL
ssay removes assay-to-assay variation and the total
umber of CTL assays can be reduced compared to the
TL testing of individual samples of PBMC. Newer, more
omplex but quantitatively more sensitive assays are
eing developed to measure virus-specific CTL memory
sing as a read-out the number of peptide-specific CD81
cells producing IFNg after stimulation (20). We recently
egan to use such an assay and preliminary results (19)
nd Jameson et al. (unpublished data) support the ob-
ervations reported here.
Materials and Methods. Volunteers. Healthy volun-
eers ages 18–45 years with no known allergy to eggs
ere recruited for the study. This was a randomized
ouble-blind controlled study enrolling adults 18–45
ears of age at a contract research organization. Prior to
nitiation, the protocol and consent were reviewed and
pproved by the institution’s ethical review committee. (ritten informed consent was obtained from all partici-
ants prior to any study activity. Prospective participants
ere screened by medical history, physical examination,
omplete and differential blood cell count, an SMA-16
iochemistry panel, urine analysis, and drug testing. Pro-
pective participants were excluded if they had received
n influenza vaccination in the previous 6 months, were
mmunocompromised, were on immunosuppressive
herapy, had a chronic illness requiring prescription med-
cation, except for oral contraceptives, or had a sus-
ected allergy to any component of the study vaccines.
emale subjects were excluded if they were pregnant or
actating and were required either to be infertile or to be
sing an effective method of contraceptive for the dura-
ion of the study. A urine pregnancy test was conducted
n all female participants just prior to vaccination. At the
ime of immunization, subjects were required to be free
f any signs or symptoms of respiratory illnesses such
s coughs or congestion. Fifty-five healthy adults were
nrolled in the study. Eleven subjects were enrolled into
ach of the five study groups: Fluzone (the licensed
tandard vaccine), 75 mg Flu-Iscoms, 50 mg Flu-Iscoms,
5 m Flu-Iscomatrix, and 50 mg Flu-Iscomatrix. Study
accine was administered by intramuscular injection into
he right or left deltoid muscle using a needle not less
han 1 in. in length. All subjects were contacted daily by
elephone for 7 days after vaccination to monitor local
nd systemic reactions. Subjects were also monitored
or 56 days after vaccination for adverse events.
Blood samples were taken for T cell studies on days 0
prevaccination) and on days 14 and 56 after vaccination.
lood samples taken on days 0, 28, and 56 were tested
or antibody responses. Serologic and safety results will
e presented in another publication. All subjects were
accinated and returned for follow-up on the same day.
ll 55 (100%) subjects completed the required follow-up
isits according to protocols.
Influenza Vaccines. The influenza antigens used to
repare the influenza Iscom vaccines were the monova-
ent subvirion concentrate pools of the 1994/1995 vac-
ine strains, A/Texas/36/91/X-113 A/Johannesburg/33/
4/RESVIR-8 and B/Harbin/7/94. These materials were
anufactured under GMP at Connaught Laboratories
nc., Swiftwater, Pennsylvania. The different formulations
ere studied to help learn which formulations would be
etter for antigen presentation and to determine whether
5 or 50 mg of Iscomatrix was more active. There were
ive study groups each with 11 volunteers who received
he standard vaccine alone, vaccine in Iscoms at 75 or 50
g, or vaccine mixed with Iscomatrix at 75 or 50 mg/
ose. All clinical and laboratory studies were performed
nder code.
Production of Influenza Iscom Trivalent Vaccines. Flu-
scom vaccines were prepared as described previously
18) with some modifications. Briefly, monovalent sub-
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260 RAPID COMMUNICATIONirion vaccine at 0.1–0.4 mg/ml in PBS (10 mM, pH 6.8,
ontaining 0.5% v/v 2-phenoxyethanol) was mixed with
hosphatidyl choline and cholesterol (each at 0.2–0.8
g/ml in 20% Mega-10) and 1–4 mg/ml Iscoprep 703
Iscotec, Lulea, Sweden) for 2 h at 25°C. Removal of
ega-10 and concentration of formed Flu-Iscoms were
chieved by diafiltration (with PBS) and ultrafiltration
sing a 30-kDa cut-off membrane (Applikon). Trivalent
lu-Iscom vaccines were prepared by combining individ-
al monovalent preparations to give the desired propor-
ion of HA and Iscoprep. Iscomatrix particles were pre-
ared as described above for Flu-Iscom monovalent vac-
ines except the Iscom particles were prepared in the
bsence of monovalent subvirion vaccine. The trivalent
lu-Iscomatrix was prepared by combining Iscomatrix
ith a mixture of the three monovalent vaccines to give
he desired proportion of HA and Iscoprep. Formation of
scom particles was verified by negative-staining elec-
ron microscopy and the HA content by single radial
mmunodiffusion (SRID) using antigen and antiserum ref-
rence standards (CBER, Bethesda, MD). The Iscoprep
ontent was determined on samples extracted with chlo-
oform–methanol and dried. Samples were reconstituted
n 30% acetonitrile and run on a C4 reverse-phase HPLC
olumn using a gradient of 30–40% acetonitrile contain-
ng 0.15% trifluoroacetic acid. The final formulations of
rivalent Flu-Iscoms and Flu-Iscomatrix comprised ap-
roximately 45 mg HA (15 mg per strain) and either 50 or
5 mg of Iscoprep per 0.5-ml dose. Trivalent vaccine was
ormulated as 45 mg HA (15 mg per strain) per 0.5-ml
ose. All vaccines passed release criteria established
or sterility, endotoxin activity, and potency.
Collection and Preparation of Blood for CTL Studies.
pproximately 60 ml of venous blood was obtained from
ach volunteer just prior to vaccination (day 0) and 14
nd 56 days after vaccination using the Vacutainer CPT
ubes (Becton Dickinson, Franklin Lakes, NJ) with so-
ium citrate. Tubes were centrifuged within 2 h of blood
ollection. Processing of the blood sample to yield
BMC were performed as recommended by the manu-
acturer. To collect the cells, the entire contents of the
ube above the gel were pipetted into a separate 50-ml
entrifuge tube, 13 PBS was added, the cells were
ixed by inverting the tube five times and centrifuged for
5 min at 300 RCF. Supernatants were aspirated and the
ell pellet was resuspended by gently vortexing, 13 PBS
as added, and cells were mixed again by inverting the
ube five times followed by centrifuging for 10 min at 200
CF. Supernatant was again aspirated and the PBMC
ere resuspended at a concentration of 1.0 3 107/ml in
PMI–20% heat-inactivated fetal bovine serum
HIFBS) 1 10% DMSO and cryopreserved in liquid nitro-
en using a programmable freezer.
CTL Assays. Preparation of effector cells. A vial of cells
rom the day 0 bleed of each donor was thawed to be lsed as stimulator cells. The cells were washed with
PMI–10% serum HIFBS and 5 3 106 cells were added to
ach of two polypropylene tubes and centrifuged. Then
.1 ml (approx. 1 3 108 PFU) of either A/TX or A/JHN virus
as added to 0.4 ml of PBS 1 0.1% bovine serum albu-
in (Gibco Life Technologies) per tube and incubated for
0 min at 37°C. Cells obtained from each donor on days,
, 14, and 56 were thawed and 5 3 106 cells were added
o each flask in RPMI–10% HIFBS medium to be used as
esponder cells. The stimulator cells were washed twice
nd 5 3 105 cells were then added to each flask of
esponder cells using three flasks of cells for each virus
timulation. Flasks were incubated for 6 days at 37°C in
% CO2 and 95% humidity. Recently reported CTL clones
19) were used as a positive control in each assay.
Target Cells and CTL Assays. EBV-transformed B-LCL
ere prepared as described previously (19). Five days
fter the bulk culture effector cells were established, 3 3
05 BLCL from each donor were infected with 0.1 ml of
ach influenza A virus diluted in 0.4 ml of RPMI–10% FBS
an m.o.i. of about 30:1) in a 48-well plate and incubated
or 14–18 h. The next day, the target cells were washed
nce and labeled with 51Cr for 60 min. The effector cells
ere washed and were added to achieve 90, 30, and 10
ffector:target ratios. Then 1.5 3 104 unlabeled K562
ells/well were added to each well to decrease NK cell
ctivity against target cells. The target cells were
ashed, 1.5 3 103 cells were added to each well in
riplicate, and plates were spun at 1000 RPM for 5 min.
he plates were incubated for 5 h at 37°C in 5% CO2 and
ere harvested using the Skatron Supernatant Collec-
ion System. The percentage specific immune lysis was
alculated by
mean CPM Exp 2 mean CPM Min
ean CPM Max ~Renex! 2 mean CPM Min
3 100
5 percentage specific immune lysis.
he Min/Max ratio is the percentage of the maximum
elease of 51Cr by detergent lysis of target cells (Max) by
he medium control wells (Min). Statistical analysis was
erformed using the Student t test to compare the means
f three replicate samples at each E:T ratio of the post-
accination to the prevaccination stimulated PBMC.
In Vitro Analysis of Target Cell Lysis by Human CD81
Cell Clones after Exposure to Influenza Vaccine and
ecombinant Proteins 6 Iscomatrix. We tested the ability
f human CD81 CTL clones to recognize autologous
-LCL following exposure to monovalent formalin-inacti-
ated detergent disrupted A/Texas (H1N1) vaccine virus
lone and after formulation into Iscom particles using an
LA-B18 restricted CD81 CTL clone specific to the H1
emagglutinin, which has been recently described (19).
accine alone containing 230 HA units or vaccine formu-ated into Iscoms containing 230 HA units was added to
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261RAPID COMMUNICATION-LCL target cells and incubated at 37°C for 1 h,
ashed, and reincubated at 37°C for 24 h followed by
51Cr labeling for use as target cells in a CTL assay with
he CTL clone. In addition we tested another CD81 CTL
lone, which is HLA-2.1 restricted and recognizes an
1-H2-H3 cross-reactive CTL epitope on NS1 aa 122–
30, for recognition of this epitope on recombinant NS1
rotein expressed in E. coli. The recombinant NS1 pro-
ein and Iscomatrix were mixed 24 h earlier and incu-
ated at 4°C before addition to target cells. The final
oncentration of NS1 protein was 35 mg/ml and the final
oncentration of saponin was 100 mg/ml. After 24 h at
°C, either the control recombinant protein or the mix-
ure of recombinant protein and Iscomatrix was added to
-LCL target cells, which were washed after 1 h, incu-
ated for 24 h at 37°C, and 51Cr labeled. The CTL assay
as performed as above.
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